JP2017505787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505787A5 JP2017505787A5 JP2016551163A JP2016551163A JP2017505787A5 JP 2017505787 A5 JP2017505787 A5 JP 2017505787A5 JP 2016551163 A JP2016551163 A JP 2016551163A JP 2016551163 A JP2016551163 A JP 2016551163A JP 2017505787 A5 JP2017505787 A5 JP 2017505787A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- nhch
- optionally
- sch
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 437
- 150000001875 compounds Chemical class 0.000 claims description 73
- -1 CH 3 Inorganic materials 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 23
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010020112 Hirsutism Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000025661 ovarian cyst Diseases 0.000 claims description 6
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 208000006155 precocious puberty Diseases 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940275P | 2014-02-14 | 2014-02-14 | |
| US61/940,275 | 2014-02-14 | ||
| US201462023773P | 2014-07-11 | 2014-07-11 | |
| US62/023,773 | 2014-07-11 | ||
| PCT/CA2015/000086 WO2015120543A1 (en) | 2014-02-14 | 2015-02-13 | Human androgen receptor dna-binding domain (dbd) compounds as therapeutics and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019056915A Division JP2019142880A (ja) | 2014-02-14 | 2019-03-25 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505787A JP2017505787A (ja) | 2017-02-23 |
| JP2017505787A5 true JP2017505787A5 (https=) | 2018-03-22 |
Family
ID=53799465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551163A Pending JP2017505787A (ja) | 2014-02-14 | 2015-02-13 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
| JP2019056915A Pending JP2019142880A (ja) | 2014-02-14 | 2019-03-25 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019056915A Pending JP2019142880A (ja) | 2014-02-14 | 2019-03-25 | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10011573B2 (https=) |
| EP (1) | EP3105229A4 (https=) |
| JP (2) | JP2017505787A (https=) |
| KR (1) | KR20160115999A (https=) |
| CN (1) | CN106164071B (https=) |
| AU (1) | AU2015218140A1 (https=) |
| BR (1) | BR112016018691A2 (https=) |
| CA (1) | CA2939048A1 (https=) |
| MX (1) | MX2016010604A (https=) |
| RU (1) | RU2016136091A (https=) |
| WO (1) | WO2015120543A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201891526A3 (ru) * | 2014-07-03 | 2019-05-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
| EP3555091A1 (en) * | 2016-12-19 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Ar-v7 inhibitors |
| WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
| US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
| CN108003148A (zh) * | 2017-12-22 | 2018-05-08 | 佛山汉方中医医院有限公司 | 异丙基哌嗪噻吩二环腈类化合物、制备方法及其用途 |
| CN108084169A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一种硝基噻吩的二环腈类化合物及其用途 |
| CN108084171A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 哌嗪噻吩二环腈类化合物、制备方法及其用途 |
| CN108129469A (zh) * | 2017-12-22 | 2018-06-08 | 佛山汉方中医医院有限公司 | 一种异丙基哌嗪硝基噻吩二环腈类化合物及其用途 |
| CN107880032A (zh) * | 2017-12-22 | 2018-04-06 | 佛山汉方中医医院有限公司 | 含噻吩的二环腈类ssao抑制剂、制备方法及其用途 |
| CN108069948A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 一种ssao抑制剂、其制备方法及其用途 |
| CN108003146A (zh) * | 2017-12-22 | 2018-05-08 | 佛山汉方中医医院有限公司 | 一类含烷氧噻吩的二环腈类ssao抑制剂、制备方法及其用途 |
| CN108069947A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 含二甲胺噻吩和异丙基哌嗪胺基结构的二环腈类化合物及用途 |
| CN108003147A (zh) * | 2017-12-22 | 2018-05-08 | 佛山汉方中医医院有限公司 | 异丙基哌嗪氟噻吩二环腈类化合物、制备方法及其用途 |
| CN107936002A (zh) * | 2017-12-22 | 2018-04-20 | 佛山汉方中医医院有限公司 | 一种异丙基哌嗪胺基噻吩二环腈类化合物及其用途 |
| CN108047213A (zh) * | 2017-12-22 | 2018-05-18 | 佛山汉方中医医院有限公司 | 一种含硫环的氟噻吩的二环腈类化合物及其用途 |
| CN108069949A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 烷基取代的哌嗪甲基噻吩二环腈类化合物、制备方法及其用途 |
| CN108084170A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一类含哌嗪烷氧噻吩结构的二环腈类化合物、制备方法及其用途 |
| CN108084168A (zh) * | 2017-12-22 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一种哌嗪噻吩二环腈类化合物、制备方法及其用途 |
| CN108069950A (zh) * | 2017-12-22 | 2018-05-25 | 佛山汉方中医医院有限公司 | 一种含噻吩的二环腈类ssao抑制剂、制备方法及其用途 |
| CN108129470A (zh) * | 2017-12-22 | 2018-06-08 | 佛山汉方中医医院有限公司 | 异丙基哌嗪噻吩二环腈类化合物、其制备方法及其用途 |
| CN108148051A (zh) * | 2017-12-22 | 2018-06-12 | 佛山汉方中医医院有限公司 | 一种含氟噻吩的二环腈类ssao抑制剂及其用途 |
| JP2022504296A (ja) * | 2018-10-03 | 2022-01-13 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 治療薬としての転写因子ｂｒｎ２阻害化合物およびそれらの使用方法 |
| JP7555938B2 (ja) * | 2019-01-30 | 2024-09-25 | モンテリノ・セラピューティクス・インコーポレイテッド | アンドロゲン受容体を標的とするユビキチン化のための二官能性化合物および方法 |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11465998B2 (en) | 2019-04-25 | 2022-10-11 | Regents Of The University Of Minnesota | Therapeutic compounds and methods of use thereof |
| JP7534390B2 (ja) * | 2019-09-12 | 2024-08-14 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| WO2021236695A1 (en) * | 2020-05-18 | 2021-11-25 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| WO2024059951A1 (en) * | 2022-09-22 | 2024-03-28 | The University Of British Columbia | Inhibitors of the androgen receptor dna-binding domain |
| US20240207415A1 (en) | 2022-11-08 | 2024-06-27 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| CN116768881B (zh) * | 2023-06-30 | 2025-09-09 | 郑州大学 | 4-(3-吲哚基)-1,3-噻唑类化合物及其制备方法和应用 |
| WO2025064918A1 (en) * | 2023-09-20 | 2025-03-27 | The Board Of Regents Of The University Of Texas System | First-in-class phospho-brd4 inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3509271A1 (de) * | 1985-03-15 | 1986-09-18 | Basf Ag, 6700 Ludwigshafen | Isothiazol-azofarbstoffe |
| DE3521406A1 (de) * | 1985-06-14 | 1986-12-18 | Bayer Ag, 5090 Leverkusen | 2,2-diaryl-chromenothiazole, ihre herstellung und ihre verwendung in aufzeichnungsmaterialien |
| JPH11209284A (ja) * | 1998-01-27 | 1999-08-03 | Sagami Chem Res Center | 骨形成促進剤 |
| TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US6451814B1 (en) * | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| EP1345914A1 (en) | 2000-12-22 | 2003-09-24 | AstraZeneca AB | Therapeutic compounds |
| US6528223B1 (en) * | 2001-11-20 | 2003-03-04 | Nexpress Solutions Llc | Magenta-colored toner particles for electrostatographic imaging |
| WO2003045930A1 (en) | 2001-11-28 | 2003-06-05 | Astrazeneca Ab | Therapeutic compounds |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| US7384966B2 (en) | 2004-08-31 | 2008-06-10 | Pharminxo Limited | 2-arylbenzothiazole derivatives |
| CN101103007A (zh) * | 2004-11-18 | 2008-01-09 | 武田药品工业株式会社 | 酰胺化合物 |
| GB0503962D0 (en) * | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
| AU2006217742A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents |
| WO2006130493A2 (en) * | 2005-05-31 | 2006-12-07 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| BRPI0717097A2 (pt) * | 2006-09-21 | 2013-11-26 | Novartis Ag | Derivados de pirrol úteis para o tratamento de doenças mediadas por citocina |
| EP2120580B1 (en) * | 2007-02-02 | 2017-12-27 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
| DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| JP5596026B2 (ja) * | 2008-06-19 | 2014-09-24 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用 |
| WO2010118347A2 (en) * | 2009-04-10 | 2010-10-14 | Zacharon Pharmaceuticals, Inc. | O-linked glycan biosynthesis modulators |
| DE102010012594A1 (de) * | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| WO2011130515A1 (en) * | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| US8642632B2 (en) * | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| EP2686317A4 (en) * | 2011-03-17 | 2014-08-20 | Selexagen Therapeutics Inc | RAF KINASE INHIBITORS |
| ES2541295T3 (es) * | 2011-04-21 | 2015-07-17 | Orion Corporation | Carboxamidas que modulan el receptor de andrógenos |
-
2015
- 2015-02-13 BR BR112016018691A patent/BR112016018691A2/pt not_active Application Discontinuation
- 2015-02-13 WO PCT/CA2015/000086 patent/WO2015120543A1/en not_active Ceased
- 2015-02-13 CN CN201580015292.9A patent/CN106164071B/zh not_active Expired - Fee Related
- 2015-02-13 JP JP2016551163A patent/JP2017505787A/ja active Pending
- 2015-02-13 MX MX2016010604A patent/MX2016010604A/es unknown
- 2015-02-13 US US15/118,652 patent/US10011573B2/en not_active Expired - Fee Related
- 2015-02-13 KR KR1020167025134A patent/KR20160115999A/ko not_active Withdrawn
- 2015-02-13 EP EP15748487.4A patent/EP3105229A4/en not_active Withdrawn
- 2015-02-13 CA CA2939048A patent/CA2939048A1/en not_active Abandoned
- 2015-02-13 AU AU2015218140A patent/AU2015218140A1/en not_active Abandoned
- 2015-02-13 RU RU2016136091A patent/RU2016136091A/ru unknown
-
2019
- 2019-03-25 JP JP2019056915A patent/JP2019142880A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505787A5 (https=) | ||
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JOP20180098A1 (ar) | : مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| PH12015501881B1 (en) | Amide compounds for the treatment of hiv | |
| RU2016136091A (ru) | Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| PH12018502457B1 (en) | Treatment for parkinson's disease | |
| TN2018000393A1 (en) | Pegylated carfilzomib compounds | |
| PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| NZ758449A (en) | Heteroaromatic compounds useful in therapy | |
| MX382765B (es) | Tratamiento para la colangitis biliar primaria. | |
| FI3273968T3 (fi) | Minosykliiniyhdisteitä biopuolustukseen | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| BR112017007426A2 (pt) | compostos aromáticos substituídos e composições farmacêuticas para prevenir e tratar osteoporose | |
| JOP20220038A1 (ar) | عوامل مضادة للملاريا | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds |